Sign inJoin waitlistJoin the waitlist

Francisco Hernandez-Ilizaliturri

Director, Community Cell Therapy · ROSWELL PARK CANCER INSTITUTE

Credentials: · ·

History

University at Buffalo School of Medicine
Present
University at Buffalo School of Medicine
Present
University at Buffalo School of Medicine
Present

Roswell Park Comprehensive Cancer Center
2002–2003
Roswell Park Comprehensive Cancer Center
2000–2002
Internal Medicine
University at Buffalo School of Medicine
1996–1999
Ignacio A. Santos School of Medicine
1991–1995

Research

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or…
The Lancet · 2022 · 698 citations
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
Blood · 2014 · 391 citations
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
Blood · 2023 · 369 citations

MC
Myron Czuczman
38 papers
Pallawi Torka
23 papers · 3 as a fellow
Ranjana Advani
20 papers
Julie Vose
19 papers
JA
Jeremy Abramson
18 papers
Nishitha Reddy
18 papers · 1 as a fellow
Leo Gordon
17 papers
Paolo Caimi
13 papers
AZ
Andrew Zelenetz
12 papers
Joachim Yahalom
12 papers
Kristie Blum
12 papers
Rachel Rabinovitch
12 papers

Clinical trials

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Principal investigator · Terminated · Phase 1
Roswell Park Cancer Institute
2024–2025
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma
Principal investigator · Active not recruiting · Phase 1
Roswell Park Cancer Institute
2014–2026
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Principal investigator · Completed · Phase 2
Roswell Park Cancer Institute
2011–2024
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
Principal investigator · Completed · Phase 2
Roswell Park Cancer Institute
2007–2016